Flotek (FTK) Q1 2026 earnings review
Data Transformation Succeeds, But Legacy Business Cracks
Flotek’s pivot to a technology-driven, Data-as-a-Service model is working exceptionally well, but its legacy foundation is showing severe stress. Total revenue grew 27% YoY to $70.1M, and Adjusted EBITDA jumped 44% to $9.1M. The star of the quarter was Data Analytics, which surged 295% and now accounts for half of the company's gross profit. However, the bottom line did not reflect this operational success—Net Income fell 13% to $4.7M due to a higher tax rate after a 2025 valuation allowance release. More concerning is a sudden 33% collapse in external chemistry revenue, completely contradicting the company's prior narrative of gaining market share in a down market.
🐂 Bull Case
The Data Analytics segment's gross profit contribution exploded from 8% a year ago to 50% today. Service revenue in this segment grew an astonishing 785% YoY, proving the high-margin recurring revenue model is highly scalable.
The company has secured over $90M in expected three-year backlog for Data Analytics, anchored by multi-year power services contracts. This insulates earnings from legacy oilfield volatility.
🐻 Bear Case
External Chemistry revenue fell 33% YoY to $14.7M. This is a massive reversal from the double-digit growth seen throughout early 2025 and signals that market headwinds are finally catching up to Flotek's core product.
The massive EPS growth narrative of 2025 was artificially inflated by a tax valuation allowance release. Now that the tax rate has normalized, Net Income and EPS are declining (-13% and -29% YoY respectively) despite strong gross profit growth.
⚖️ Verdict: ⚪
Cautiously Optimistic. Flotek is successfully executing one of the hardest maneuvers in business—pivoting to a higher-margin technology model. However, the sudden deterioration in the legacy external chemistry business creates a massive drag that investors cannot ignore.
Key Themes
The DaaS Transformation is Complete
Data Analytics (DA) is no longer just a growth story; it is the financial engine of the company. DA revenue grew 295% YoY to $10.4M. More importantly, service revenues (recurring) grew 785% to $8.5M. The segment now generates 50% of total company gross profit, up from just 8% in Q1 2025, completely changing Flotek's margin profile and reducing its reliance on cyclical chemical sales.
External Chemistry Narrative Breaks
Reversing trend. Throughout 2025, management touted their 'Prescriptive Chemistry Management' as a tool to gain market share despite declining rig counts (growing 88% YoY in Q1 25 and 38% YoY in Q2 25). That narrative broke this quarter. External chemistry revenues collapsed 33% YoY to $14.7M. This specific data point directly contradicts the prior narrative of immunity to market cyclicality.
Power Services Contract Ramp
The PWRtek acquisition is delivering tangible, long-term visibility. Flotek announced a new power services contract in early March for up to 50 MW of federal disaster recovery support. This pushes their expected 3-year recurring backlog to over $90M. It also successfully proves Flotek can sell outside of traditional oil and gas applications.
XSPCT Analyzer Commercialization
Technology innovation continues to drive adoption. The XSPCT spectrometer, recently named 2026 Product of the Year at the Analyzer Technology Conference, replaces legacy Gas Chromatography. It delivers real-time composition analysis directly in the stream, solving custody transfer inaccuracies and creating a highly defensible moat for the Data Analytics segment.
Increasing Dependency on Related Party
While external chemistry plummeted, related-party chemistry (primarily ProFrac) jumped 46% YoY to $44.9M. Consequently, related-party sales now make up a staggering 75% of total chemistry revenue, up from 58% a year ago. This concentration risk leaves Flotek heavily exposed to the capital allocation decisions of a single major partner.
Net Income Hurt by Tax Normalization
Reversing trend. Net Income fell 13% YoY to $4.7M and EPS dropped 29%. This is not an operational failure, but a structural headwind: Flotek enjoyed an artificially low tax rate in 2025 due to a valuation allowance release on deferred tax assets. Investors looking purely at bottom-line GAAP profitability will see a deceleration story throughout 2026.
Macro Shift into Power Generation
Management explicitly highlighted the 'convergence of real-time data and chemistry' driving an 'industrial pivot.' Flotek is using its gas measurement tech to facilitate natural gas utilization for turbines and dual-fuel engines across the broader energy infrastructure grid. This macro shift away from upstream completions towards general power infrastructure drastically expands their Total Addressable Market (TAM).
Other KPIs
Stable. Gross margin was virtually flat YoY (22.2% vs 22.5%). Despite the massive shift toward higher-margin Data Analytics, the 64% reduction in high-margin minimum purchase shortfall penalties ($2.7M vs $7.5M last year) masked the underlying operational margin improvement.
Accelerating slightly. Grew 10% YoY due to higher non-cash stock compensation costs. However, as a percentage of revenue, SG&A improved by 100 basis points to 10% from 11% in Q1 2025, demonstrating excellent operating leverage as top-line revenue scales.
Guidance
Decelerating. The $280M midpoint implies roughly 18% YoY growth compared to FY25 actuals. While strong, this represents a deceleration from the 27% growth posted in Q1 2026, implying management expects growth to cool down in the remaining quarters, likely due to the ongoing drag from external chemistry sales.
Decelerating. The midpoint of $38.5M implies ~17% YoY growth. Similar to revenue, this is a cool-down from the 44% YoY Adjusted EBITDA growth printed in Q1 2026. However, if achieved, it will mark the fourth consecutive year of profitability expansion.
Key Questions
External Chemistry Collapse
External chemistry revenues fell 33% YoY this quarter, completely breaking the narrative that Prescriptive Chemistry Management was immune to market cycles. Is this a permanent step-down in market share, or was there a one-time disruption?
ProFrac Dependency
With related-party chemistry now accounting for 75% of segment sales, what is the contingency plan if ProFrac decides to aggressively scale back its completions activity in the second half of 2026?
Data Analytics Margins
Data Analytics generated 50% of gross profit on just 15% of total revenue. As the 50 MW disaster recovery power contract ramps up, will the gross margin profile of these utility-scale contracts match or dilute the ~70%+ margins seen in the upstream DA business?